Patents
Literature
4 results about "LDL receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The Low-Density Lipoprotein (LDL) Receptor (LDL-R) is a mosaic protein of 839 amino acids (after removal of 21-amino acid signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100, which is embedded in the outer phospholipid layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). In humans, the LDL receptor protein is encoded by the LDLR gene on chromosome 19. It belongs to the Low density lipoprotein receptor gene family. It is most significantly expressed in bronchial epithelial cells and adrenal gland and cortex tissue.
A pathological diagnosis biomarker combination of adrenal origin cushing's syndrome and application thereof
The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.
Owner:THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY
Engineered viral particles for targeted delivery
PCT designated stageWO2026107131A3Virus peptidesOther foreign material introduction processesViral glycoproteinAutoimmune condition
Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).
Owner:ORBITAL THERAPEUTICS INC
Engineered viral particles for targeted delivery
PCT designated stageWO2026107131A2SsRNA viruses negative-senseVirus peptidesAutoimmune conditionAutoimmune disease
Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).
Owner:ORBITAL THERAPEUTICS INC
Crispr-related methods and compositions targeting low-density lipoprotein receptor (LDLR)
The present disclosure relates to genome editing systems and components for targeting, editing, and / or modulating the expression of a target nucleic acid sequence of interest, e.g., an LDLR target nucleic acid sequence in the 3' untranslated region (UTR) of the gene encoding the LDLR protein. The present disclosure is also directed to methods and applications thereof in connection with the treatment and / or management of hypercholesterolemia.
Owner:EDITAS MEDICINE INC +9